Molecular structure of Nilotinib, CAS Number: 641571-10-0
Nilotinib (CAS 641571-10-0)
See product citations (9)
Application:
Nilotinib is a rationally designed c-Abl and Bcr-Abl kinase inhibitor
CAS Number:
641571-10-0
Purity:
≥99%
Molecular Weight:
529.5
Molecular Formula:
C28H22F3N7O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Nilotinib is a small molecule Bcr-Abl kinase inhibitor, rationally designed to bind and inhibit the c-Abl kinase active site with more affinity than the prototypic Bcr-Abl kinase inhibitor Imatinib (sc-202180). Nilotinib demonstrates a high affinity for the kinase (IC50 < 30nM) and shows efficacy against chronic myelogenous leukemias (CML) expressing the Bcr-Abl oncogene/fusion protein, both the wild type and CMLs presenting Imatinib resistance.
Nilotinib (CAS 641571-10-0) References
- In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. | O'Hare, T., et al. 2005. Cancer Res. 65: 4500-5. PMID: 15930265
- AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. | Golemovic, M., et al. 2005. Clin Cancer Res. 11: 4941-7. PMID: 16000593
- AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. | Weisberg, E., et al. 2006. Br J Cancer. 94: 1765-9. PMID: 16721371
- Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. | Kantarjian, H., et al. 2006. N Engl J Med. 354: 2542-51. PMID: 16775235
- Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors. | McFarland, KL. and Wetzstein, GA. 2009. Cancer Control. 16: 132-40. PMID: 19337199
- Nilotinib-associated vascular events. | Quintás-Cardama, A., et al. 2012. Clin Lymphoma Myeloma Leuk. 12: 337-40. PMID: 22633167
- Nilotinib-associated acute pancreatitis. | Engel, T., et al. 2013. Ann Pharmacother. 47: e3. PMID: 23300151
- Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation. | Contreras, O., et al. 2018. Skelet Muscle. 8: 5. PMID: 29463296
- Deleterious reproductive effects of nilotinib in mouse model. | Ozkavukcu, S., et al. 2021. Reproduction. 161: 295-306. PMID: 33428589
- Nilotinib, A Tyrosine Kinase Inhibitor, Suppresses the Cell Growth and Triggers Autophagy in Papillary Thyroid Cancer. | Meng, L., et al. 2022. Anticancer Agents Med Chem. 22: 596-602. PMID: 33797387
- Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer. | Wang, S., et al. 2021. Neoplasma. 68: 975-982. PMID: 34263649
- Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson's disease models. | Wu, J., et al. 2021. Int Immunopharmacol. 99: 108025. PMID: 34364303
- A case report of nilotinib-induced irreversible interstitial lung disease. | Cho, JY., et al. 2022. Medicine (Baltimore). 101: e28701. PMID: 35089229
- Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling. | Kim, J., et al. 2022. J Neuroinflammation. 19: 187. PMID: 35841100
- Nilotinib alleviated acetaminophen-induced acute hepatic injury in mice through inhibiting HIF-1alpha/VEGF-signaling pathway. | Menisy, GM., et al. 2022. Int Immunopharmacol. 112: 109268. PMID: 36182876
Inhibitor of:
α-chimaerin, β-defensin 42, β-defensin 43, β-defensin 50, β-defensin 8, 1810043G02Rik, 2900053A13Rik, 3Gn-T6, 4922501L14Rik, 4930408F14Rik, 4933416I08Rik, 9330182O14Rik, ABCG8, Abin-1, Abl, AF-4, AI182371, AI316807, AKIP, AML-2, ARK-3, ARV1, Arxes2, ASCC2, Axotrophin, B230380D07Rik, BAALC, BC034069, BCAR3, Bcl-2, Bcr, Blk, BSPH1, c-Abl, c-Kit, C11orf94, C330019G07Rik, C330019L16Rik, C5orf34_4833420G17Rik, C6orf145, Cbl-3, CCT B, CD45, CD93, CEACAM19, CEACAM20, CHMP5, CHST1, CIP2A, CLLD6, CMS, CNK1, CXorf64, CYBASC3, cyclin K, CYHR1, DC-TM4F2, DCIR2, DDR2, DLEC1, Dok-4, Dok-5, Dok-6, DSN1, E-Ras, EF-CAB10, EFR3A, EG667705, Eos, Eph A8, ETL, EVI2B, FAK, FAXC, Fes, FIP1L1, gankyrin, GAPT, GGH, Gm128, Gm14325, Gm5894, Gm960, GRASP, GRIP-1, HBV xAg, Hepatocellular Carcinoma Marker, IGSF10, ILEI, INSL5, IRR, KHS, KIAA1522, KKIAMRE, KLHL11, KNP-I, LAIR-1, Laminin α-4, LAT2, LERK-3, LIN-3, Lipin-3, LOC100041418, LOC440087, LTK, MARCH (membrane associated ring-CH-type finger), Mare, MAST1, MAST4, Melanoma, MTERF, NET-4, Niban, NK10, NOK, NUCKS, Olfr1253, Olfr209, Olfr385, Olfr39, Olfr628, Olr1002, Olr104, Olr1052, Olr1060, Olr1065, Olr107, Olr110, Olr111, Olr1199, Olr1203, Olr1220, Olr1231, Olr1234, Olr1257, Olr1286, Olr129, Olr1292, Olr1293, Olr1295, Olr130, Olr1307, Olr1321, Olr1323, Olr1330, Olr1331, Olr1383, Olr1384, Olr1398, Olr144, Olr150, Olr153, Olr1560, Olr1561, Olr1576, Olr159, Olr160, Olr163, Olr1630, Olr1641, Olr1657, Olr168, Olr1718, Olr1733, Olr1748, Olr185, Olr282, Olr309, Olr354, Olr361, Olr367, Olr375, Olr395, Olr410, Olr440, Olr484, Olr496, Olr515, Olr516, Olr554, Olr575, Olr577, Olr592, Olr598, Olr607, Olr608, Olr712, Olr734, Olr742, Olr748, Olr769, Olr772, Olr785, Olr791, Olr80, Olr83, Olr838, Olr889, Olr92, Olr920, Olr943, Olr951, Olr956, Olr996, OTTMUSG00000004968, OTTMUSG00000010332, OTTMUSG00000010432, OTTMUSG00000011282, OTTMUSG00000016453, OTTMUSG00000019138, Parkin, PATE-N, PB1, Pbx 2, PDGF-A, PDGF-B, PDGFR-beta, PEAR1, PFTAIRE-1, PINK1, Ppp2r3d, Prolifera, Protein tyrosine phosphatase receptor (PTPR), PTPγ, PTPκ, PTPRQ, Ran BP-5, RHAMM, Rhox3, RNF213, Rootletin, RREB1, RUSC2, Sad-1, SBK1, SCGBL, SENP8, Septin 11, Sfta2, SGS2, SH2D (SH2 domain containing protein), SH3PXD2B, Shc, Shc4, Sipa1l3, Skint9, Slap, Sm D1, Spot-2, Sprr2a2, ST, StARD9, SUP, Svs7, T3JAM, Tau-1, Tau-2, TCP-c, TDF, TEL, TEM7R, TESK1, TESSP1, TFIP11, TGFβ2, TGFβ3, TLCD1, TM, TMC3, TMEM114, Trav13d-4, Trav2, TREM-2c, Twist, Txk, Tyrosine Kinase, UGT1A5, UNC5H3, V1RI6, VHY, Vmn2r60, VSIG10L, and XAGE-1.Activator of:
Bcr, Cables1, Clusterin, DOCK 7, Dok-3, EDG-2, eIF3θ, GPNMB, LRRK2, MAP LC3β2, Mast Cell Protease 9, P23, PDGFR-B, Pim-2, Ran BP-5, Rbx1, SKAP55-R, SOCS-3, TIP120A, UBE1Y1, USP9Y, and WDR48.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nilotinib, 10 mg | sc-202245 | 10 mg | $205.00 | |||
Nilotinib, 25 mg | sc-202245A | 25 mg | $405.00 |